...
【24h】

HMG-CoA Reductase Inhibitors and the Risk of Vertebral Fracture.

机译:HMG-CoA还原酶抑制剂和椎骨骨折的风险。

获取原文
获取原文并翻译 | 示例
           

摘要

Statins inhibit an enzyme in the mevalonate pathway and therefore may affect bone. In this first study on both symptomatic and nonsymptomatic vertebral fractures in the elderly (N = 3469), we show that long-term statin use is significantly associated with a 50% lower vertebral fracture risk. Randomized trials on statins and fractures, carried out in populations at risk for fractures, are needed. INTRODUCTION: Statins are cholesterol-lowering agents that could potentially affect bone. Previous studies on statin use and fracture risk reported contradictory results and did not include both symptomatic and nonsymptomatic vertebral fractures. MATERIALS AND METHODS: To examine the association between statin use, vertebral fractures, and lumbar spine BMD, we performed a prospective population-based cohort study in men and women (N = 3469) >/=55 years of age. These individuals had both baseline and follow-up spinal X-rays available. Statin use was obtained from detailed computerized pharmacy data, and the total number of days of exposure before second X-ray was calculated. A multivariate logistic regression model was fitted to calculate odds ratios and CIs. RESULTS: During a mean follow-up of 6.5 years, 176 incident vertebral fractures occurred. There were 508 statin users and 16 exposed cases. The adjusted relative risk for incident vertebral fracture in users of statins (compared with nonusers) was 0.58 (95% CI, 0.34-0.99). The relative risk decreased on higher cumulative use to 0.52 (95% CI, 0.28-0.97) for use for more than 365 days during the study period. Use of (the hydrophilic statin) pravastatin and use of nonstatin cholesterol-lowering drugs was not significantly associated with vertebral fracture risk. Statin use was not significantly associated with lumbar spine BMD. CONCLUSION: Statin use is associated with a lower risk of vertebral fracture. Randomized clinical trials in a population at risk for fracture are needed to examine this association.
机译:他汀类药物抑制甲羟戊酸途径中的一种酶,因此可能会影响骨骼。在这项针对老年人有症状和无症状椎骨骨折的首次研究中(N = 3469),我们表明长期使用他汀类药物与降低50%椎骨骨折风险显着相关。他汀类药物和骨折的随机试验需要在有骨折风险的人群中进行。简介:他汀类药物是降低胆固醇的药物,可能会影响骨骼。先前关于他汀类药物使用和骨折风险的研究报告了相互矛盾的结果,没有同时包括有症状和无症状的椎骨骨折。材料与方法:为了研究他汀类药物使用,椎骨骨折与腰椎骨密度之间的关系,我们对男性和女性(N = 3469)≥55岁进行了前瞻性人群研究。这些人都有基线和后续的脊柱X射线可用。从详细的计算机化药房数据中可获得他汀类药物的使用,并计算出第二次X射线照射前的总暴露天数。拟合多元逻辑回归模型以计算比值比和CI。结果:在平均6.5年的随访期间,发生了176例椎骨骨折。他汀类药物使用者508名,暴露病例16例。他汀类药物使用者(与非使用者)相比经调整的发生椎体骨折的相对风险为0.58(95%CI,0.34-0.99)。在研究期间,超过365天使用更高的累积使用量,相对风险降低至0.52(95%CI,0.28-0.97)。使用(亲水性他汀类)普伐他汀和使用非他汀类降胆固醇药物与椎体骨折风险无显着相关性。他汀类药物的使用与腰椎骨密度没有显着相关。结论:他汀类药物的使用与较低的椎骨骨折风险相关。需要对有骨折风险的人群进行随机临床试验以检查这种关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号